Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer

American Journal of Pathology

Volumn 188, Issue 6, 2018, Pages 1478-1485

  Haffner, Michael C ^a,b   Guner, Gunes ^b   Taheri, Diana ^b   Netto, George J ^a,b   Palsgrove, Doreen N ^b   Zheng, Qizhi ^b   Guedes, Liana Benevides ^b   Kim, Kunhwa ^a   Tsai, Harrison ^c   Esopi, David M ^a   Lotan, Tamara L ^a,b   Sharma, Rajni ^b   Meeker, Alan K ^a,b   Chinnaiyan, Arul M ^d   Nelson, William G ^a,b   Yegnasubramanian, Srinivasan ^a,b   Luo, Jun ^a,b   Mehra, Rohit ^d   Antonarakis, Emmanuel S ^a,b   Drake, Charles G ^a   De Marzo, Angelo M ^a,b   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROGRAMMED DEATH 1 LIGAND 1; VISMODEGIB; CD274 PROTEIN, HUMAN; TUMOR MARKER;

ACINAR CELL CARCINOMA; ANTIBODY LABELING; ARTICLE; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DISTANT METASTASIS; FLOW CYTOMETRY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPHOBLAST CELL LINE; MAJOR CLINICAL STUDY; MALE; METASTATIC PROSTATE CANCER; MICROSATELLITE INSTABILITY; MOLECULAR WEIGHT; PREVALENCE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN TARGETING; SENSITIVITY AND SPECIFICITY; SMALL CELL CARCINOMA; TREATMENT RESPONSE; WESTERN BLOTTING; ADENOCARCINOMA; COHORT ANALYSIS; EVALUATION STUDY; METABOLISM; METASTASIS; PATHOLOGY; PREDICTIVE VALUE; PROSTATE TUMOR; SECONDARY;

ADENOCARCINOMA; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; COHORT STUDIES; HUMANS; MALE; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS;

EID: 85047136400     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2018.02.014     Document Type: Article

References (43)

1. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., Leming, P.D., Spigel, D.R., Antonia, S.J., Horn, L., Drake, C.G., Pardoll, D.M., Chen, L., Sharfman, W.H., Anders, R.A., Taube, J.M., McMiller, T.L., Xu, H., Korman, A.J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G.D., Gupta, A., Wigginton, J.M., Sznol, M., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
2. Brahmer, J.R., Tykodi, S.S., Chow, L.Q.M., Hwu, W.-J., Topalian, S.L., Hwu, P., Drake, C.G., Camacho, L.H., Kauh, J., Odunsi, K., Pitot, H.C., Hamid, O., Bhatia, S., Martins, R., Eaton, K., Chen, S., Salay, T.M., Alaparthy, S., Grosso, J.F., Korman, A.J., Parker, S.M., Agrawal, S., Goldberg, S.M., Pardoll, D.M., Gupta, A., Wigginton, J.M., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (2012), 2455–2465.
3. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (2012), 252–264.
4. Ribas, A., Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov 5 (2015), 915–919.
5. Taube, J.M., Klein, A., Brahmer, J.R., Xu, H., Pan, X., Kim, J.H., Chen, L., Pardoll, D.M., Topalian, S.L., Anders, R.A., Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20 (2014), 5064–5074.
6. Hirsch, F.R., McElhinny, A., Stanforth, D., Ranger-Moore, J., Jansson, M., Kulangara, K., Richardson, W., Towne, P., Hanks, D., Vennapusa, B., Mistry, A., Kalamegham, R., Averbuch, S., Novotny, J., Rubin, E., Emancipator, K., McCaffery, I., Williams, J.A., Walker, J., Longshore, J., Tsao, M.-S., Kerr, K.M., PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 12 (2017), 208–222.
7. Aggen, D.H., Drake, C.G., Biomarkers for immunotherapy in bladder cancer: a moving target. J Immunother Cancer, 5, 2017, 94.
8. Sunshine, J., Taube, J.M., PD-1/PD-L1 inhibitors. Curr Opin Pharmacol 23 (2015), 32–38.
9. Calagua, C., Russo, J., Sun, Y., Schaefer, R., Lis, R., Zhang, Z., Mahoney, K.M., Bubley, G.J., Loda, M., Taplin, M.-E., Balk, S.P., Ye, H., Expression of PD-L1 in hormone-naïve and treated prostate cancer patients receiving neoadjuvant abiraterone acetate plus prednisone and leuprolide. Clin Cancer Res 23 (2017), 6812–6822.
10. Topalian, S.L., Drake, C.G., Pardoll, D.M., Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27 (2015), 450–461.
11. Baas, W., Gershburg, S., Dynda, D., Delfino, K., Robinson, K., Nie, D., Yearley, J.H., Alanee, S., Immune characterization of the programmed death receptor pathway in high risk prostate cancer. Clin Genitourin Cancer 15 (2017), 577–581.
12. Martin, A.M., Nirschl, T.R., Nirschl, C.J., Francica, B.J., Kochel, C.M., van Bokhoven, A., Meeker, A.K., Lucia, M.S., Anders, R.A., DeMarzo, A.M., Drake, C.G., Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis 18 (2015), 325–332.
13. Gevensleben, H., Dietrich, D., Golletz, C., Steiner, S., Jung, M., Thiesler, T., Majores, M., Stein, J., Uhl, B., Müller, S., Ellinger, J., Stephan, C., Jung, K., Brossart, P., Kristiansen, G., The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer. Clin Cancer Res 22 (2016), 1969–1977.
14. McLaughlin, J., Han, G., Schalper, K.A., Carvajal-Hausdorf, D., Pelekanou, V., Rehman, J., Velcheti, V., Herbst, R., LoRusso, P., Rimm, D.L., Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol 2 (2016), 46–54.
15. Graff, J.N., Alumkal, J.J., Drake, C.G., Thomas, G.V., Redmond, W.L., Farhad, M., Cetnar, J.P., Ey, F.S., Bergan, R.C., Slottke, R., Beer, T.M., Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget 7 (2016), 52810–52817.
16. Kantoff, P.W., Schuetz, T.J., Blumenstein, B.A., Glode, L.M., Bilhartz, D.L., Wyand, M., Manson, K., Panicali, D.L., Laus, R., Schlom, J., Dahut, W.L., Arlen, P.M., Gulley, J.L., Godfrey, W.R., Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28 (2010), 1099–1105.
17. Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F., Redfern, C.H., Ferrari, A.C., Dreicer, R., Sims, R.B., Xu, Y., Frohlich, M.W., Schellhammer, P.F., IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363 (2010), 411–422.
18. Schweizer, M.T., Drake, C.G., Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev 33 (2014), 641–655.
19. Schweizer, M.T., Antonarakis, E.S., Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol 4 (2012), 167–178.
20. Gannon, P.O., Poisson, A.O., Delvoye, N., Lapointe, R., Mes-Masson, A.-M., Saad, F., Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 348 (2009), 9–17.
21. Bishop, J.L., Sio, A., Angeles, A., Roberts, M.E., Azad, A.A., Chi, K.N., Zoubeidi, A., PD-L1 is highly expressed in enzalutamide resistant prostate cancer. Oncotarget 6 (2015), 234–242.
22. Grasso, C.S., Wu, Y.-M., Robinson, D.R., Cao, X., Dhanasekaran, S.M., Khan, A.P., Quist, M.J., Jing, X., Lonigro, R.J., Brenner, J.C., Asangani, I.A., Ateeq, B., Chun, S.Y., Siddiqui, J., Sam, L., Anstett, M., Mehra, R., Prensner, J.R., Palanisamy, N., Ryslik, G.A., Vandin, F., Raphael, B.J., Kunju, L.P., Rhodes, D.R., Pienta, K.J., Chinnaiyan, A.M., Tomlins, S.A., The mutational landscape of lethal castration-resistant prostate cancer. Nature 487 (2012), 239–243.
23. Robinson, D., Van Allen, E.M., Wu, Y.-M., Schultz, N., Lonigro, R.J., Mosquera, J.-M., et al. Integrative clinical genomics of advanced prostate cancer. Cell 161 (2015), 1215–1228.
24. Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E., Antipin, Y., Reva, B., Goldberg, A.P., Sander, C., Schultz, N., The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2 (2012), 401–404.
25. Tsai, H.K., Lehrer, J., Alshalalfa, M., Erho, N., Davicioni, E., Lotan, T.L., Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma. BMC Cancer, 17, 2017, 759.
26. Haffner, M.C., Aryee, M.J., Toubaji, A., Esopi, D.M., Albadine, R., Gurel, B., Isaacs, W.B., Bova, G.S., Liu, W., Xu, J., Meeker, A.K., Netto, G., De Marzo, A.M., Nelson, W.G., Yegnasubramanian, S., Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 42 (2010), 668–675.
27. Udager, A.M., Shi, Y., Tomlins, S.A., Alva, A., Siddiqui, J., Cao, X., Pienta, K.J., Jiang, H., Chinnaiyan, A.M., Mehra, R., Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer. Prostate 74 (2014), 1199–1208.
28. Maughan, B.L., Suzman, D.L., Luber, B., Wang, H., Glavaris, S., Hughes, R., Sullivan, R., Harb, R., Boudadi, K., Paller, C., Eisenberger, M., Demarzo, A., Ross, A., Antonarakis, E.S., Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol 78 (2016), 1297–1304.
29. Antonarakis, E.S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J.C., Chen, Y., Mohammad, T.A., Chen, Y., Fedor, H.L., Lotan, T.L., Zheng, Q., De Marzo, A.M., Isaacs, J.T., Isaacs, W.B., Nadal, R., Paller, C.J., Denmeade, S.R., Carducci, M.A., Eisenberger, M.A., Luo, J., AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371 (2014), 1028–1038.
30. Zhu, Y., Sharp, A., Anderson, C.M., Silberstein, J.L., Taylor, M., Lu, C., Zhao, P., De Marzo, A.M., Antonarakis, E.S., Wang, M., Wu, X., Luo, Y., Su, N., Nava Rodrigues, D., Figueiredo, I., Welti, J., Park, E., Ma, X.-J., Coleman, I., Morrissey, C., Plymate, S.R., Nelson, P.S., de Bono, J.S., Luo, J., Novel junction-specific and quantifiable in situ detection of AR-V7 and its clinical correlates in metastatic castration-resistant prostate cancer. Eur Urol 73 (2017), 727–735.
31. Gaule, P., Smithy, J.W., Toki, M., Rehman, J., Patell-Socha, F., Cougot, D., Collin, P., Morrill, P., Neumeister, V., Rimm, D.L., A quantitative comparison of antibodies to programmed cell death 1 ligand 1. JAMA Oncol 3 (2016), 256–259.
32. Faith, D.A., Isaacs, W.B., Morgan, J.D., Fedor, H.L., Hicks, J.L., Mangold, L.A., Walsh, P.C., Partin, A.W., Platz, E.A., Luo, J., De Marzo, A.M., Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. Prostate 61 (2004), 215–227.
33. Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., Skora, A.D., Luber, B.S., Azad, N.S., Laheru, D., Biedrzycki, B., Donehower, R.C., Zaheer, A., Fisher, G.A., Crocenzi, T.S., Lee, J.J., Duffy, S.M., Goldberg, R.M., la Chapelle de, A., Koshiji, M., Bhaijee, F., Huebner, T., Hruban, R.H., Wood, L.D., Cuka, N., Pardoll, D.M., Papadopoulos, N., Kinzler, K.W., Zhou, S., Cornish, T.C., Taube, J.M., Anders, R.A., Eshleman, J.R., Vogelstein, B., Diaz, L.A., PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 (2015), 2509–2520.
34. Reinhold, W.C., Sunshine, M., Liu, H., Varma, S., Kohn, K.W., Morris, J., Doroshow, J., Pommier, Y., CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res 72 (2012), 3499–3511.
35. Sunshine, J.C., Nguyen, P.L., Kaunitz, G.J., Cottrell, T.R., Berry, S., Esandrio, J., Xu, H., Ogurtsova, A., Bleich, K.B., Cornish, T.C., Lipson, E.J., Anders, R.A., Taube, J.M., PD-L1 expression in melanoma: a quantitative immunohistochemical antibody comparison. Clin Cancer Res 23 (2017), 4938–4944.
36. Ness, N., Andersen, S., Khanehkenari, M.R., Nordbakken, C.V., Valkov, A., Paulsen, E.-E., Nordby, Y., Bremnes, R.M., Donnem, T., Busund, L.-T., Richardsen, E., The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort. Oncotarget 8 (2017), 26789–26801.
37. Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O'Brien, M., Rao, S., Hotta, K., Leiby, M.A., Lubiniecki, G.M., Shentu, Y., Rangwala, R., Brahmer, J.R., KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375 (2016), 1823–1833.
38. Kataoka, K., Shiraishi, Y., Takeda, Y., Sakata, S., Matsumoto, M., Nagano, S., et al. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature 534 (2016), 402–406.
39. Ansell, S.M., Lesokhin, A.M., Borrello, I., Halwani, A., Scott, E.C., Gutierrez, M., Schuster, S.J., Millenson, M.M., Cattry, D., Freeman, G.J., Rodig, S.J., Chapuy, B., Ligon, A.H., Zhu, L., Grosso, J.F., Kim, S.Y., Timmerman, J.M., Shipp, M.A., Armand, P., PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372 (2015), 311–319.
40. Ribas, A., Hu-Lieskovan, S., What does PD-L1 positive or negative mean?. J Exp Med 213 (2016), 2835–2840.
41. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., Miller, M.L., Rekhtman, N., Moreira, A.L., Ibrahim, F., Bruggeman, C., Gasmi, B., Zappasodi, R., Maeda, Y., Sander, C., Garon, E.B., Merghoub, T., Wolchok, J.D., Schumacher, T.N., Chan, T.A., Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
42. Guedes, L.B., Antonarakis, E.S., Schweizer, M.T., Mirkheshti, N., Almutairi, F., Park, J.C., Glavaris, S., Hicks, J., Eisenberger, M.A., De Marzo, A.M., Epstein, J.I., Isaacs, W.B., Eshleman, J.R., Pritchard, C.C., Lotan, T.L., MSH2 loss in primary prostate cancer. Clin Cancer Res 23 (2017), 6863–6874.
43. Schweizer, M.T., Cheng, H.H., Tretiakova, M.S., Vakar-Lopez, F., Klemfuss, N., Konnick, E.Q., Mostaghel, E.A., Nelson, P.S., Yu, E.Y., Montgomery, B., True, L.D., Pritchard, C.C., Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. Oncotarget 7 (2016), 82504–82510.